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(13–31) and 6 (2–12). A human factors analysis of the
circumstances of each case attributed 79% to a combi-
nation of user error and device malfunction or ﬂawed
alarm design. None of the events were documented in the
medical record or in incident reports. CONCLUSIONS:
Rates of alarm related problems in two ICUs were much
higher than reported in a routine reporting system and
indicate an understudied important threat to patient
safety. An assessment of risk factors for these events is in
progress.
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OBJECTIVES: To describe the pattern of use of alterna-
tive therapy, healthcare spending, and health-related
quality of life in Chinese osteoarthritis (OA) patients in
Hong Kong. METHODS: We conducted a retrospective,
cross-sectional study of 547 adult Chinese patients in
Hong Kong who have been diagnosed as having OA. We
deﬁned the alternative therapy as 1 of the 11 therapies
outlined in international publications. OA patients who
used alternative therapies and those who did not were
compared for their socio-economic status, disease proﬁle,
personal healthcare spending, and quality of life. Quality
of life was measured using a Health Utility Index based
upon SF-36 health surveys. We further investigated the
association between the use of alternative therapies and
personal healthcare spending, and its association with the
Health Utility Index, in multivariate regressions control-
ling for socio-economic variables, years of OA, and the
severity of OA. RESULTS: Of the 547 OA patients, 219
(38.2%) had used 1 or more of the 11 alternative thera-
pies for OA. The most commonly used therapies, (and the
percentage of patients who used them), were acupuncture
(21.4%), exercise (12%), herbal remedy (5.9%), lifestyle
diets (5.8%), energy healing (4.4%), and chiropractic
manipulation (3.8%). On average, payment for alterna-
tive therapies constitutes 5% of the overall personal
healthcare spending, and 29% of the out-of-pocket pay-
ments. CONCLUSION: The use of alternative therapies
was statistically signiﬁcantly associated with higher per-
sonal healthcare spending, after adjusting for socioeco-
nomic variables, years of OA and severity of OA. The use
of alternative therapies was not signiﬁcantly associated
with an improvement in quality of life in the regression
analysis.
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OBJECTIVES: Prior authorization (PA) is a poorly
studied, but commonly employed policy used by health
care payers to manage the rising costs of pharmacy 
beneﬁts. Our objective was to evaluate the impact of PA
policies for cyclooxygenase-2 (COX-2) inhibitors on 
prescription drug and medical service utilization in a
managed care Medicaid population. METHODS: The
analysis was conducted from January 1, 1999 to October
31, 2001 when PA policies were enacted for celecoxib and
rofecoxib. Monthly annualized rates of utilization were
estimated using medical and prescription drug billing
records. An autocorrelation-corrected segmented linear
regression model was developed to evaluate trends in 
utilization temporally associated with PA initiation. 
The primary analysis evaluated utilization of related 
drug classes (e.g. conventional NSAIDs, PPIs), and ofﬁce,
emergency, and hospital encounters in all enrolled
members. A secondary analysis was performed in a
cohort of prior NSAID (conventional and COX-2) users.
RESULTS: After each PA was activated, utilization 
of celecoxib and rofecoxib were immediately reduced
from 1.07 to 0.53 days supply/person-year (58.9% re-
duction; 95% CI: 50.0%–67.9%) and 0.96 to 0.52 
days supply/person-year (49.8% reduction; 95% CI:
40.5%–59.1%), respectively. Growth in utilization was
slowed for both agents (p < 0.0001). Utilization changes
were not observed in other drug classes. Similar trends
were observed in the secondary analysis. No changes 
in medical service use were noted with the exception of
emergency room visits, which increased by 18.0% (95%
CI: 2.2%–33.9%) and exhibited a higher growth rate
after the PA for celecoxib was enacted. A similar, non-
signiﬁcant trend was observed in the secondary analysis.
CONCLUSIONS: Utilization of rofecoxib and celecoxib
was reduced substantially following the implementation
of a PA policy. No important concomitant changes in the
use of other drug classes were detected. The small increase
in ER visits observed after the celecoxib PA was activated
is a concerning ﬁnding that warrants further study.
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OBJECTIVES: To analyze the market impact of the in-
troduction of the COX-2 inhibitors, Celebrex and Vioxx,
